Open AccessFc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Author(s) -
Shuying S. Li,
Peter B. Gilbert,
Lindsay N. Carpp,
ChulWoo Pyo,
Holly Janes,
Youyi Fong,
Xiaoying Shen,
Scott D. Neidich,
Derrick Goodman,
Allan C. deCamp,
Kristen W. Cohen,
Guido Ferrari,
Scott M. Hammer,
Magdalena E. Sobieszczyk,
Mark J. Mulligan,
Susan Buchbinder,
Michael C. Keefer,
Edwin DeJesus,
Richard M. Novak,
Ian Frank,
M. Juliana McElrath,
Georgia D. Tomaras,
Daniel E. Geraghty,
Xinxia Peng
Publication year - 2019
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.02041-18
Subject(s) - haplotype , single nucleotide polymorphism , biology , immunology , vaccine trial , hiv vaccine , regimen , virology , snp , minor allele frequency , allele , medicine , genotype , genetics , vaccination , gene
By analyzing data from the HVTN 505 efficacy trial of a DNA/recombinant adenovirus 5 (rAd5) vaccine regimen, we found that host genetics, specifically Fc gamma receptor genetic variations, influenced whether receiving the DNA/rAd5 regimen was beneficial, neutral, or detrimental to an individual with respect to HIV-1 acquisition risk. Moreover, Fc gamma receptor genetic variations influenced immune responses to the DNA/rAd5 vaccine regimen. Thus, Fc gamma receptor genetic variations should be considered in the analysis of future HIV vaccine trials and the development of HIV vaccines.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom